Insulin degludec
Insulin analogues have revolutionized the treatment of diabetes mellitus, and the advent of newer insulin analogues have provided better glycemic control with lesser incidence of hypoglycemia. Insulin degludec is a second-generation, ultra-long-acting acylated basal insulin analogue that possesses a...
Saved in:
Main Authors: | Vishakha V Jain (Author), Omprakash Gupta (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2013-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
by: Minze MG, et al.
Published: (2016) -
Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
by: Qiong Luo, et al.
Published: (2022) -
The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021) -
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
by: Rendell M
Published: (2017) -
Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China
by: Guangxin Han, et al.
Published: (2022)